These cells are able to block CD8 T-cell-mediated tumor recognition and clearance thereby contributing to the profound resistance against novel therapies based on new therapeutic interventions like checkpoint inhibitor targeting or inhibitors and cancer vaccines [93]. Here, CD8A is linked to neoplasm.